Visualizing the immune response to pathogens

Current Opinion in Immunology
Aparna Srinivasan, Stephen J McSorley

Abstract

Advances in immune visualization have enabled the physical tracking of immune responses in vivo. The adaptation of such technology to models of infectious disease holds the promise of a more detailed analysis of host-pathogen interactions in a natural setting. However, the visualization of pathogen-specific immune responses in vivo confronts challenges that are inherent to the study of infectious disease systems. Recent attempts to track pathogen-specific immune responses in vivo validate the usefulness and underline the complexity of this experimental strategy.

References

Sep 19, 2000·Life Sciences·B Spellberg
Mar 13, 2001·Annual Review of Immunology·M K JenkinsK A Pape
Sep 6, 2001·Proceedings of the National Academy of Sciences of the United States of America·T ZellM K Jenkins
Jan 10, 2002·The Journal of Experimental Medicine·Daniel J Campbell, Eugene C Butcher
Feb 19, 2002·Nature Immunology·Ian C Boulton, Scott D Gray-Owen
Mar 6, 2002·The Journal of Experimental Medicine·Joseph N BlattmanRafi Ahmed
Apr 3, 2002·The Journal of Experimental Medicine·Huji XuMichael F Good
Jun 8, 2002·Science·Sabine StollRonald N Germain
Jun 11, 2002·Nature Immunology·Vladimir P BadovinacJohn T Harty
Aug 28, 2002·Immunity·Daniel B StetsonRichard M Locksley
Oct 9, 2002·The Journal of Experimental Medicine·Eulogia RománSusan L Swain
Feb 26, 2003·Proceedings of the National Academy of Sciences of the United States of America·Mark J MillerIan Parker
Mar 18, 2003·Nature Immunology·Amanda V GettJens Geginat
Mar 18, 2003·Nature Immunology·Marianne J B van StipdonkStephen P Schoenberger
Apr 2, 2003·Nature Reviews. Immunology·Allan McI Mowat
May 6, 2003·Nature Immunology·Philippe Bousso, Ellen Robey
Jul 4, 2003·Nature·J Rodrigo MoraUlrich H Von Andrian
Sep 30, 2003·European Journal of Immunology·Matthias SchiemannDirk H Busch
Dec 17, 2003·The Journal of Experimental Medicine·Marianna BoncristianoCosima T Baldari
Jan 9, 2004·Nature·Thorsten R MempelUlrich H Von Andrian
Jan 15, 2004·Proceedings of the National Academy of Sciences of the United States of America·Mark J MillerIan Parker

❮ Previous
Next ❯

Citations

Jun 25, 2005·Immunology Letters·Rosa Maria Salazar-Gonzalez, Stephen J McSorley
Feb 15, 2012·Proceedings of the National Academy of Sciences of the United States of America·Seung-Joo LeeStephen J McSorley
Jul 7, 2007·Proceedings of the National Academy of Sciences of the United States of America·Rajesh RavindranStephen J McSorley
Apr 5, 2005·Immunology·Rajesh Ravindran, Stephen J McSorley
Jun 20, 2014·Immunological Reviews·Stephen J McSorley
Jul 13, 2004·Current Opinion in Immunology·Tom H M Ottenhoff, Michael J Bevan
Jan 20, 2015·Future Microbiology·Oanh H Pham, Stephen J McSorley
Nov 10, 2011·Toxins·Maddalena de VirgilioMaria Serena Fabbrini
May 4, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Aparna SrinivasanStephen J McSorley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Antigenic Modulation

Antigenic modulation occurs when an antibody cross-links antigens on a cell surface, causing the antigens to become internalized. This can lead to therapeutic failure of monoclonal antibodies as the expression of the antigen becomes decreased on target cells. Find the latest research on antigenic modulation here.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.